hyperCORE International has announced Nicholas Focil as its new president, a decision that underscores the network's commitment to strengthening its position in the global clinical research arena. Focil, with his extensive background in clinical operations and strategic partnerships, is expected to lead hyperCORE into new heights of innovation and diversity in clinical trials.
Focil's leadership at FOMAT Medical Research, where he focused on ethical, high-quality, and diverse clinical data, aligns with hyperCORE's mission. His appointment is seen as a pivotal step for the network, which has over 80 active trial sites across five countries and two continents, to further its impact in the clinical research space.
The outgoing president, Carlos Orantes, expressed confidence in Focil's ability to continue the network's path of excellence. Focil, in turn, acknowledged Orantes's contributions and the solid foundation laid for future growth. With a vision to enhance site capabilities and broaden the reach of trials, Focil's leadership is anticipated to bring about more diverse and high-quality research beneficial to patients and sponsors alike.
This leadership transition comes at a time when hyperCORE International is experiencing dynamic growth, highlighting the network's role in advancing clinical research through safe, ethical, and efficient studies. Focil's expertise and vision are expected to further hyperCORE's commitment to operational excellence and patient-centered care in the evolving landscape of clinical research.
